The Oesophageal Cancer Risk Test is a blood-based assessment designed to support evaluation of oesophageal adenocarcinoma risk in appropriate patients presenting with chronic reflux symptoms and recognised risk factors.
Chronic gastro-oesophageal reflux disease (GORD) is a recognised risk factor for oesophageal adenocarcinoma.
Many patients are diagnosed at later stages of disease, while current assessment pathways frequently rely on invasive investigation through endoscopy.
There is an increasing need for non-invasive approaches to assist risk assessment and support referral decisions.
Suitable for adults who:
The test analyses four protein biomarkers associated with oesophageal adenocarcinoma and combines these with clinical variables including age, sex and BMI to generate a personalised risk score.
Results are reported as:
With guidance regarding further investigation pathways.
The Oesophageal Cancer Risk Test may assist clinicians by:
PromarkerESO can be requested by using a standard pathology request form. The test is exclusively available through pathology network and is performed on a routine blood sample.
Results help identify patients whose risk profile may warrant further investigation or specialist referral, alongside clinical assessment and existing management pathways.
PromarkerESO is currently a privately funded test and is not covered by Medicare.
Please refer to current pricing information for patient out-of-pocket costs and payment arrangements.
PromarkerESO requires a routine blood sample collected at a participating Laverty Pathology collection centre.
No specialised collection procedure is required. Specimens are transported to the testing laboratory under validated conditions for analysis.
